Marc Lustig - 14 May 2024 Form 4 Insider Report for BriaCell Therapeutics Corp. (BCTX)

Role: Director, 10%+ Owner
Signature: /s/ Marc Lustig
Issuer symbol: BCTX
Transactions as of: 14 May 2024
Transactions value $: $2,000,001
Form type: 4
Filing time: 20 May 2024, 16:00:14 UTC
Previous filing: 02 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCTX	Common Shares	Purchase	$2,000,001	+902,935	+55%	$2.22	2,542,935	14 May 2024	By L5 Capital Inc.	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCTX	Common Stock Warrants	Purchase		+902,935			902,935	14 May 2024	Common Stock	902,935	$2.11	By L5 Capital Inc.	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.

Content

The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.